TFF3 and colitis: Both TFF1 and TFF3 have been the subject of clinical trials: TFF3 was administered to colitis patients30 and a Lactococcus lactis strain engineered to secrete TFF1 is being administered to patients undergoing chemoradiation therapy to combat oral mucositis (clinicaltrials.gov ID NCT03234465).